Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
5(36%)
Results Posted
57%(4 trials)

Phase Distribution

Ph phase_1
5
36%
Ph phase_2
4
29%
Ph phase_3
3
21%
Ph phase_4
1
7%

Phase Distribution

5

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
5(38.5%)
Phase 2Efficacy & side effects
4(30.8%)
Phase 3Large-scale testing
3(23.1%)
Phase 4Post-market surveillance
1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

14

all time

Status Distribution
Active(7)
Completed(7)

Detailed Status

Completed7
Recruiting5
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
14
Active
5
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (38.5%)
Phase 24 (30.8%)
Phase 33 (23.1%)
Phase 41 (7.7%)

Trials by Status

recruiting536%
completed750%
not_yet_recruiting214%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT06321601Phase 3

Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.

Recruiting
NCT07556484Phase 1

Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube

Recruiting
NCT06072482Phase 4

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Recruiting
NCT06468826Phase 1

A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

Completed
NCT07373262Phase 3

Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement

Not Yet Recruiting
NCT06676579Phase 2

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

Recruiting
NCT07176546Phase 2

TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

Not Yet Recruiting
NCT02994927Phase 3

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Completed
NCT03852472Phase 2

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

Completed
NCT03301467Phase 2

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

Completed
NCT06758271

Special Drug Use-results Survey for Long-term Use(Avacopan)

Recruiting
NCT06207682Phase 1

Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin

Completed
NCT06004934Phase 1

A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

Completed
NCT05988034Phase 1

A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14